Objective: To describe a registry set up to monitor children treated with etanercept in Germany
and Austria. Methods: Giannini’s criteria, duration of morning stiffness, number of swollen, …

Objective To develop criteria for the classification of macrophage activation syndrome (MAS)
in patients with systemic juvenile idiopathic arthritis (JIA). Methods A multistep process, …

Background Interleukin-1 is pivotal in the pathogenesis of systemic juvenile idiopathic arthritis
(JIA). We assessed the efficacy and safety of canakinumab, a selective, fully human, anti–…

Background Tumor necrosis factor (TNF) has a pathogenic role in juvenile rheumatoid
arthritis. We evaluated the efficacy and safety of adalimumab, a fully human monoclonal anti-TNF …

Introduction: The development of biologics has markedly changed the treatment of JIA.
Complete control of the disease and remission has today become the main goal of treatment …

Background Rare autoinflammatory diseases (AIDs) including Cryopyrin-Associated Periodic
Syndrome (CAPS), Tumor Necrosis Receptor-Associated Periodic Syndrome (TRAPS) and …

Objective Juvenile localized scleroderma is usually considered a disease that is confined to
the skin and subcutaneous tissue. We studied the prevalence and clinical features of …

Background We compared the safety and efficacy of leflunomide with that of methotrexate in
the treatment of polyarticular juvenile rheumatoid arthritis in a multinational, randomized, …

Objective To evaluate the interleukin-6 receptor inhibitor tocilizumab for the treatment of
patients with polyarticular-course juvenile idiopathic arthritis (pcJIA). Methods This three-part, …

Recent therapeutic advances in juvenile idiopathic arthritis (JIA) have made remission an
achievable goal for most patients. Reaching this target leads to improved outcomes. The …